Effect of Oral Methyl Prednisolone on Different Radiological Patterns of Hypersensitivity Pneumonitis

Figures & data

Figure 1 HRCT of chest for patient with fibrosis.

Figure 2 HCRT of chest for showing mosaic attenuation.

Figure 3 HRCT of chest showing ground glass opacities.

Figure 4 HRCT of chest showing centrilobular nodules.

Table 1 Descriptive Data of the Patients

	Fibrotic HP		Non-Fibrotic HP		P value
Age (years)	49.48± 13.31		50.53±10.21		0.746
Height (m)	1.65± 0.1		1.67±0.12		0.728
Weight (Kg)	95.71± 22.2		93.16± 27.57		0.723
BMI	35 ±7.66		33.11±6.78		0.348
Sex	Count	%	Count	%	p value
Male	8	38.10%	12	37.50%	0.965
Female	13	61.90%	20	62.50%

Note: Data is presented as mean ± standard deviation (SD) or as patient numbers (%).

Abbreviation: BMI, body mass index.

Table 2 Comparison Between fHP Group and nfHP Group After Taking Methylprednisolone 0.5mg/Kg/Day of for Eight Weeks

	Fibrotic HP	Non-Fibrotic HP		Mosaic Attenuation nfHP	Centrilobular Nodules nfHP	Ground Glass Opacities nfHP
	Mean	Mean	P value	Mean	Mean	Mean	P value
FEV1 change after eight weeks (L)	7.72 ± 6.55	11.97±4.12	< 0.001	11.91 ±4.06	12.1 ± 4.65	11.91 ± 4.09	0.826
FVC change after eight weeks (L)	6.95 ± 5.12	11.12±3.03	< 0.001	9.82 ± 2.48	12.18 ± 3.61	11.45 ± 2.73	0.159
Oximetry change before exertion after eight weeks (%)	2.19 ± 1.6	3.5 ±1.97	0.003	4.36 ± 1.86	3.4 ± 1.65	2.73 ± 2.15	0.279
Oximetry change after exertion after eight weeks (%)	1.78 ± 3.04	5.17 ±2.83	0.001	6.18 ± 2.79	5.2 ± 2.35	3.89 ± 3.14	0.214
Six-minute walk change after eight weeks (m)	25 ± 15.43	44.33 ±19.02	0.001	48.18 ± 17.79	38 ± 19.32	46.67 ± 20.46	0.365

Note: Data is presented as mean ± standard deviation (SD).

Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.

Figure 5 Comparing the effect of methyl prednisolone between fibrotic and non-fibrotic groups after finishing the designated treatment course regarding FEV1 (A), FVC (B), oximetry before exertion (C), oximetry after exertion (D), six-minute walk test (E): black (Fhp), blue (nfHP). All p values are significant.

Table 3 Fibrotic Patient’s Improvement After Taking 0.5mg/Kg/Day of Methylprednisolone for Eight Weeks

	Fibrotic HP
	Mean	p value
FEV1 at week 0 (L)	51.17±6.41	<0.001
FEV1 at week 8 (L)	58.89±10.44
FVC at week 0 (L)	46.07±6.58	<0.001
FVC at week 8 (L)	53.02±8.62
Oximetry at week 0 before exertion (%)	89.67±3.86	<0.001
Oximetry at week 8 before exertion (%)	91.86±4.04
Oximetry at 0 after exertion (%)	80.56±6.20	<0.001
Oximetry at week 8 after exertion (%)	81.90±5.07
Six-minute walk test at week 0 (m)	232.22±49.53	<0.001
Six-minute walk test at week 8 (m)	246.67±57.82

Note: Data is presented as mean ± standard deviation (SD).

Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.

Figure 6 Comparing the effect of methyl prednisolone between non-fibrotic subgroups after finishing the designated treatment course regarding FEV1 (A), FVC (B), oximetry before exertion (C), oximetry after exertion (D), six-minute walk test (E): black (mosaic attenuation nfHP), gray (centrilobular nodules nfHP), blue (GGO’S nfHP). All p values are non-significant.